MedTrace Logo

Choline and Brain Functioning in Postmenopausal Women

NCT07264257 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-12-04

No results posted yet for this study

Summary

This study will use a randomized placebo-controlled trial to examine a single oral dose of 1650 mg choline influences brain functioning as measured by fMRI.

Conditions

Interventions

DIETARY_SUPPLEMENT

Choline

Each subject gets one 1650 mg oral choline dose or placebo on each of two study days.

DIETARY_SUPPLEMENT

Placebo

Each subject gets one 1650 mg oral choline dose or placebo on each of two study days.

Sponsors & Collaborators

  • Balchem Corporation

    collaborator INDUSTRY

  • University of Vermont

    lead OTHER

Principal Investigators

  • Julie A Dumas, PhD · University of Vermont

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2022-12-20
Completion
2025-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264257 on ClinicalTrials.gov